Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
1496552-51-2	Chloro Sofosbuvir Chloro Sofosbuvir is an impurity of Sofosbuvir; a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled Sofosbuvir as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
1502654-87-6	Ledipasvir D-tartrate Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively). GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing.
1502655-48-2	Ledipasvir diacetone Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.006 nM), A30V (EC(50) = 0.012 nM), and E92A (EC(50) = 0.004 nM) while the NS5A-A30K and -Y93H variants exhibited reduced sensitivity to DCV (EC50 values of 23 nM and 1120 nM, respectively) and to GS-5885 (EC50 values of 1770 nM and 4300 nM, respectively). GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Plasma pharmacokinetics was consistent with QD dosing.
1509904-96-4	Cyclophilin inhibitor 1 Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin inhibitor, and it shows effective anti-HCV activity, with an EC50 of 98 nM for HCV 2a.
151271-53-3	UK-1 UK-1, a benzoxazol derivative, has been found to be a Streptomyces metabolite that could exhibit anticancer activity and topoisomerase II restraination activity.
1535212-07-7	Voxilaprevir Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity. Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively. Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research.
15574-49-9	Mecarbinate Mecarbinate is a chemical intermediate of arbidol hydrochloride.
1606150-08-6	BMS-986144 BMS-986144, a third-generation, pan-genotype (GT) NS3/4A protease inhibitor, inhibits HCV replicon with EC50s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively.
1621884-22-7	2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate sodium salt PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting HCV NS5B polymerases, with IC50s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively.
1676100-30-3	Cyclophilin-inhibitor-3 Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC50 of 4.2 M).
176652-07-6	Artemisinin-[d3] Artemisinin-[d3] is the labelled analogue of Artemisinin. Artemisinin is a natural product originally isolated from plants of the genus Artemisia. It effectively kills malarial parasites of the genus Plasmodium. It is usually used in combination therapy for the treatment of malaria. Artemisinin is also used against a wide range of trematodes, including Schistosoma.
182959-28-0	YM-53601 free base YM-53601 free base is a squalene synthase inhibitor with an IC50 of 79 nM for human hepatoma cells. It is a lipid lowering agent that can reduce plasma cholesterol and triglyceride levels in vivo. It is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and can inhibit the proliferation of HCV.
182959-33-7	YM-53601 YM-53601 is a squalene synthase inhibitor with IC50s of 79 and 90 nM in HepG2 cells and rat liver microsomes, respectively. It is a lipid lowering agent that can reduce plasma cholesterol and triglyceride levels in vivo and inhibit cholesterol biosynthesis in rats (ED50 = 32 mg/kg). It is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and can inhibit the proliferation of HCV.
1868135-06-1	Sofosbuvir-[d6] Sofosbuvir-[d6] is the labelled analogue of Sofosbuvir. Sofosbuviis a medication used for the treatment of hepatitis C.
1903800-11-2	KIN1408 KIN1408 is an IRF3 activator with antiviral activity. It induces innate immune gene expression such as MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells stimulated with phorbol 12-myristate 12-acetate (PMA).
1919828-83-3	DDX3-IN-1 DDX3-IN-1 is a DEAD-box polypeptide 3 (DDX3) inhibitor for HCV and HIV, respectively.
1966138-53-3	Coblopasvir-dihydrochloride Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection.
198821-22-6	Merimepodib Merimepodib is orally bioavailable IMPDH inhibitor.
1998705-62-6	HCV-IN-31 HCV-IN-31 is an inhibitor of HCV, with an EC50/EC95 of 15.7 μM for HCV replicon.
1998705-64-8	Bemnifosbuvir Bemnifosbuvir is the precursor drug form of the antiviral nucleoside analogue AT-9010. It reduces the infectious virus yield in cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome CoV (SARS-CoV), SARS-CoV-2, human CoV 229E (HCoV-229E), and HCoV-OC43 (EC90s = 37, 0.47, 2.8, 1.2, and 0.5 µM, respectively).

※ Please kindly note that our services are for research use only.